基于哥斯塔丁-M连体的CAR-T疗法显示出强大的抗瘤活性,可以对抗骨髓瘤
Daniel Feinberg1, Vinayak Uppin2, Saada Eid3
1Department of Pathology, Case Western Reserve University, Cleveland, OH, USA.
BMC medicine
|March 17, 2026
概括
这项研究引入了一种新的基于连接体的CAR-T疗法,使用oncostatin M (OSM) 向骨髓瘤,一种具有挑战性的骨癌. 在临床前模型中,OSM CAR-T细胞表现出显著的抗瘤效应,提供了一个有前途的新治疗途径.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 癌症生物学 癌症生物学
背景情况:
- 由于抗原异质性,CAR-T疗法在固体瘤中显示出有限的疗效.
- 骨肉瘤是一种骨癌,几十年来一直存在停滞不前的治疗选择.
- 在骨髓瘤中, Kostatin M (OSM) 受体 (OSMR/LIFR) 的表达高.
研究的目的:
- 探索基于连接体的CAR-T细胞的治疗潜力,这些细胞向骨髓瘤中的OSM受体.
- 开发一种CAR-T方法来克服固体瘤中的抗原异质性.
主要方法:
- 工程第三代CAR-T细胞表达人类的OSM.
- 使用了体外共同化试验和体内异种移植模型 (包括转移模型)
- 来自患者的样本和新的PDX模型 (KKOS) 评估了受体表达和CAR-T细胞敏感性.
主要成果:
- 在OSM CAR-T细胞对骨髓瘤细胞系和患者样本 in vitro 和 in vivo 显示出显著的细胞毒性.
- 观察到目标特异性细胞因子释放 (IFNγ).
- 静脉注射OSM CAR-T细胞在多个小鼠模型中减少了瘤负担,包括转移性和耐治疗的骨髓瘤.
结论:
- 基于人体配体的OSM CAR-T细胞在骨髓瘤中表现出强大的抗瘤活性.
- 临床前数据支持OSM CAR-T细胞作为骨髓瘤的可行的新治疗策略.
- 需要对OSM CAR-T细胞进行进一步的研究,以治疗骨髓瘤.
相关概念视频
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
02:57Targeted Cancer Therapies
1.7K
1.7K
02:49Cancer Therapies
10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
03:03mTOR Signaling and Cancer Progression
5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.0K
02:34Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K